BRPI0807613A2 - Ativação de antígeno humano presente em células através de clec-6 - Google Patents

Ativação de antígeno humano presente em células através de clec-6

Info

Publication number
BRPI0807613A2
BRPI0807613A2 BRPI0807613-8A2A BRPI0807613A BRPI0807613A2 BR PI0807613 A2 BRPI0807613 A2 BR PI0807613A2 BR PI0807613 A BRPI0807613 A BR PI0807613A BR PI0807613 A2 BRPI0807613 A2 BR PI0807613A2
Authority
BR
Brazil
Prior art keywords
clec
cells
human antigen
antigen activation
activation present
Prior art date
Application number
BRPI0807613-8A2A
Other languages
English (en)
Inventor
Jacques F Banchereau
Dapeng Li
Sandra Zurawski
Gerard Zurawski
Sangkon Oh
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of BRPI0807613A2 publication Critical patent/BRPI0807613A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0807613-8A2A 2007-02-23 2008-02-22 Ativação de antígeno humano presente em células através de clec-6 BRPI0807613A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89141807P 2007-02-23 2007-02-23
PCT/US2008/054785 WO2008103947A2 (en) 2007-02-23 2008-02-22 Activation of human antigen-presenting cells through clec-6

Publications (1)

Publication Number Publication Date
BRPI0807613A2 true BRPI0807613A2 (pt) 2014-06-10

Family

ID=39710781

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807613-8A2A BRPI0807613A2 (pt) 2007-02-23 2008-02-22 Ativação de antígeno humano presente em células através de clec-6

Country Status (14)

Country Link
US (1) US20080254047A1 (pt)
EP (1) EP2129692A4 (pt)
JP (1) JP2010519313A (pt)
KR (1) KR20090118981A (pt)
CN (2) CN102586186A (pt)
AU (1) AU2008218184B2 (pt)
BR (1) BRPI0807613A2 (pt)
CA (1) CA2717656A1 (pt)
IL (2) IL200526A0 (pt)
MX (1) MX2009008918A (pt)
NZ (2) NZ579238A (pt)
TW (1) TW200900078A (pt)
WO (1) WO2008103947A2 (pt)
ZA (1) ZA200906618B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130036246A (ko) * 2010-05-07 2013-04-11 베일러 리서치 인스티튜트 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
KR102025848B1 (ko) 2010-12-01 2019-11-05 앨더바이오 홀딩스 엘엘씨 항―ｎｇｆ 조성물 및 그의 용도
JP6262218B2 (ja) * 2012-06-14 2018-01-17 エラスムス ユニバーシティ メディカルセンター ロッテルダムＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｒｏｔｔｅｒｄａｍ 微小残存病変を検出するための方法、試薬およびキット。
EP3013362B1 (en) 2013-06-28 2021-08-04 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
CA2936833A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2942101A1 (en) 2014-03-21 2015-09-24 Abbvie Inc. Anti-egfr antibodies and antibody drug conjugates
IL297905A (en) 2015-07-28 2023-01-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
CN105510598A (zh) * 2015-12-31 2016-04-20 中国科学院海洋研究所 长牡蛎CgNatterin-3重组蛋白的应用
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
IL300274A (en) 2016-06-08 2023-04-01 Abbvie Inc Antibodies against B7–H3 and conjugates of drug and antibody
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
BR112018075653A2 (pt) 2016-06-08 2019-08-27 Abbvie Inc anticorpos anti-b7-h3 e conjugados anticorpo fármaco
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
ES2883678T3 (es) * 2016-10-21 2021-12-09 Inst Nat Sante Rech Med Métodos para promover la respuesta de linfocitos T
WO2018195302A1 (en) 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
AU2018290880A1 (en) * 2017-06-28 2020-01-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for Dectin-2 stimulation and cancer immunotherapy
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
KR20220004634A (ko) 2019-03-15 2022-01-11 볼트 바이오테라퓨틱스 인코퍼레이티드 Her2를 표적으로 하는 면역접합체
CN110373385A (zh) * 2019-07-12 2019-10-25 赛德特生物科技开发有限公司 改善神经细胞功能的免疫细胞培养基及其制备方法与应用
KR20230042691A (ko) 2020-06-04 2023-03-29 카리스마 테라퓨틱스 인코포레이티드 키메라 항원 수용체에 대한 신규한 작제물
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114315990B (zh) * 2022-03-10 2022-05-27 北京康乐卫士生物技术股份有限公司 新型冠状病毒特异性单克隆抗体的制备及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) * 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
AU2003213640A1 (en) * 2002-02-28 2003-09-16 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20040091503A1 (en) * 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
US7666596B2 (en) * 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
CA2715042C (en) * 2007-02-02 2021-02-02 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody

Also Published As

Publication number Publication date
US20080254047A1 (en) 2008-10-16
KR20090118981A (ko) 2009-11-18
IL200526A0 (en) 2010-04-29
WO2008103947A2 (en) 2008-08-28
ZA200906618B (en) 2010-06-30
IL216778A0 (en) 2012-01-31
WO2008103947A3 (en) 2008-11-27
TW200900078A (en) 2009-01-01
EP2129692A2 (en) 2009-12-09
AU2008218184A1 (en) 2008-08-28
CN101668777A (zh) 2010-03-10
NZ579238A (en) 2012-04-27
NZ595319A (en) 2012-09-28
EP2129692A4 (en) 2010-12-15
MX2009008918A (es) 2009-09-14
CA2717656A1 (en) 2008-08-28
AU2008218184B2 (en) 2013-01-10
CN102586186A (zh) 2012-07-18
JP2010519313A (ja) 2010-06-03

Similar Documents

Publication Publication Date Title
BRPI0807613A2 (pt) Ativação de antígeno humano presente em células através de clec-6
BRPI0821262A2 (pt) Célula fotovoltaica e dispositivo fotovoltaico
BRPI0807160A2 (pt) vacinas baseadas no direcionamento de antígeno ao dcir expresso em células apresentadoras de antígeno
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
FR2928157B1 (fr) Module de cellule habitable et cellule habitable correspondante
SI2949666T1 (sl) Človeška anti alfa-sinukleinska protitelesa
BRPI0818349A2 (pt) Dispositivo de reconstrução
BRPI0811448A2 (pt) Arranjo de vedação e acomodação térmica em dispositivos de led.
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
FR2929217B1 (fr) Dispositif de connexion en deux parties
EP2084185A4 (en) HUMAN ANTIBODIES THAT NEUTRALIZE HUMAN METAPNEUMOVIRUS
FR2932082B1 (fr) Dispositif de soutien, notamment lombaire
BRPI1008083A2 (pt) linhagem de células humanas permanentes inéditas
BRPI0814572A2 (pt) Célula de lítio
IL217209A0 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
BRPI0923652A2 (pt) diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
BRPI0813726A2 (pt) Célula de lítio
EP2344533A4 (en) SPECIFIC HUMAN ANTIBODY OF TMPRSS4
EP2297306A4 (en) HUMAN FACILITATING CELLS
EP2321320A4 (en) NEW COMPOUNDS AND THEIR USES IN DIAGNOSIS
FI20075699A (fi) Polttokennolaitteisto
DE602008003994D1 (de) Fahrzeugsitz-Schiebevorrichtung
EP2262049A4 (en) NEW PHOTOSENSIBILIZER AND PHOTOVOLTAIC ITEM
DK1991092T3 (da) Rygstätteindretning
GB0812277D0 (en) Antibody and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.